These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19022927)

  • 21. Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection.
    Shen Y; Pielop J; Hsu S
    Arch Dermatol; 2005 Jan; 141(1):102-3. PubMed ID: 15655158
    [No Abstract]   [Full Text] [Related]  

  • 22. Nonischemic cardiomyopathy related to pegylated interferon and ribavirin.
    Choy-Shan A; Berezovskaya S; Zinn A; Sedlis SP; Bini EJ
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1438-40. PubMed ID: 19907230
    [No Abstract]   [Full Text] [Related]  

  • 23. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 24. Interstitial pneumonia recurrence during chronic hepatitis C treatment.
    Renou C; Germain S; Harafa A; Martin S; Larroque O; Muller P; Bertrand JJ; Halfon P
    Am J Gastroenterol; 2005 Jul; 100(7):1625-6. PubMed ID: 15984999
    [No Abstract]   [Full Text] [Related]  

  • 25. Hematologic side effects of PEG interferon and ribavirin. Management with growth factors.
    Keeffe EB; Kowdley KV
    J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S1-2. PubMed ID: 15597022
    [No Abstract]   [Full Text] [Related]  

  • 26. A case of irreversible alopecia associated with ribavirin and peg-interferon therapy.
    Shafa S; Borum ML; Igiehon E
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):122-3. PubMed ID: 19959941
    [No Abstract]   [Full Text] [Related]  

  • 27. Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon.
    Veldt BJ; Schalm SW; Janssen HL
    J Clin Gastroenterol; 2007 Apr; 41(4):432. PubMed ID: 17413616
    [No Abstract]   [Full Text] [Related]  

  • 28. Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin.
    Miura Y; Kami M; Yotsuya R; Toda N; Komatsu T
    Am J Hematol; 2008 Sep; 83(9):758-9. PubMed ID: 18615552
    [No Abstract]   [Full Text] [Related]  

  • 29. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin.
    Watanabe T; Inoue M; Harada K; Homma N; Uchida M; Ogata N; Funada R; Hasegawa K; Soga K; Shibasaki K
    Gut; 2006 Nov; 55(11):1682-3. PubMed ID: 17047132
    [No Abstract]   [Full Text] [Related]  

  • 30. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 31. Interferon-induced thyroid dysfunction--not always transient.
    Wong VW; Cheng AY; Chan HL
    J Gastroenterol Hepatol; 2009 Jun; 24(6):938-40. PubMed ID: 19638076
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of pouchitis with combination therapy with peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery.
    Morimoto K; Yamagami H; Hosomi S; Ohira M; Suekane T; Kamata N; Sogawa M; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Tamori A; Oshitani N; Arakawa T
    Am J Gastroenterol; 2009 Jun; 104(6):1609-10. PubMed ID: 19491886
    [No Abstract]   [Full Text] [Related]  

  • 33. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
    J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
    [No Abstract]   [Full Text] [Related]  

  • 34. Acute pancreatitis associated with the use of peginterferon.
    Ozdogan O; Tahan V; Cincin A; Imeryuz N; Tozun N
    Pancreas; 2007 May; 34(4):485-7. PubMed ID: 17446854
    [No Abstract]   [Full Text] [Related]  

  • 35. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Enjoji M; Dainichi T; Gondo H; Urabe K
    Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
    Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
    Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
    [No Abstract]   [Full Text] [Related]  

  • 37. Interferon alfa: hyperpigmentation.
    Prescrire Int; 2014 Nov; 23(154):268. PubMed ID: 25954797
    [No Abstract]   [Full Text] [Related]  

  • 38. [Side effects of the combined antiviral therapy in patients with chronic hepatitis C].
    Vashakidze ET; Gegeshidze TN; Zhamutashvili MT; Svanidze MB
    Georgian Med News; 2007; (148-149):26-8. PubMed ID: 17921538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Hayashi M; Kataoka Y; Tachikawa K; Koguchi H; Tanaka H
    Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.